Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 6, Pages 729-734
Publisher
Informa Healthcare
Online
2016-03-22
DOI
10.1517/13543784.2016.1169273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)
- (2016) Clive S. Zent et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review
- (2016) Scott C. Howard et al. ANNALS OF HEMATOLOGY
- Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors
- (2016) Rossana Maffei et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Structural, conformational and thermodynamic aspects ofgroove-directed-intercalationof flavopiridol into DNA
- (2016) Bhumika Ray et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
- (2015) Kami Maddocks et al. AMERICAN JOURNAL OF HEMATOLOGY
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
- (2015) J. C. Byrd et al. BLOOD
- Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
- (2015) Philip A. Thompson et al. CANCER
- Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro
- (2015) Daniela Cihalova et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model
- (2015) Min-Sun Kwak et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure
- (2015) Uri Rozovski et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
- (2015) David M. Lucas et al. LEUKEMIA & LYMPHOMA
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
- (2015) Mark C. Lanasa et al. LEUKEMIA RESEARCH
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
- (2015) Joshua F. Zeidner et al. LEUKEMIA RESEARCH
- Ofatumumab for the treatment of chronic lymphocytic leukemia
- (2015) Sebastian Grosicki Expert Review of Hematology
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth
- (2014) Yue Song et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial
- (2014) Glen A Kennedy et al. LANCET ONCOLOGY
- Antitumor Effects of Flavopiridol on Human Uterine Leiomyoma In Vitro and in a Xenograft Model
- (2014) Hyun-Gyo Lee et al. Reproductive Sciences
- Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
- (2013) Emilia Mahoney et al. Autophagy
- A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
- (2013) J. Ji et al. CLINICAL CANCER RESEARCH
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
- (2013) Deborah M. Stephens et al. LEUKEMIA RESEARCH
- ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
- (2012) E. Mahoney et al. BLOOD
- Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
- (2012) D. M. Stephens et al. HAEMATOLOGICA
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
- (2012) S. K. Jain et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
- (2011) K A Blum et al. LEUKEMIA
- The binding of flavopiridol to blood serum albumin
- (2010) Daniel Myatt et al. CHIRALITY
- Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone
- (2010) H. Kodaira et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
- (2010) Wenjun Ni et al. PLoS One
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
- (2008) S.-R. A. Hussain et al. BLOOD
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- A novel liposomal formulation of flavopiridol
- (2008) X YANG et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More